METTL16 and acute myeloid leukemia: These findings reveal a critical role for the METTL16/m6A–BCAT1/2–BCAA axis in AML pathogenesis and stem cell regulation, highlighting METTL16’s role in epitranscriptomic and metabolic reprogramming as a driver of leukemogenesis and a potential therapeutic target (28).